Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Large Intestinal Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Intestinal Neoplasm
Large Intestinal Neoplasm

Subtype

Large Intestinal Neoplasm

CI-CAN-00001062Explore in graph →

Non-malignant1,847 active trials21 approved drugs383 evidence items

NCIt: C215201

Overview
Statistics
Survival
Genomics27
Variants & evidence383
Drugs80
Trials8849
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (370)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 226–250 of 370 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
· Lancet Oncol · 2011 · PMID 21163703 · validated civic_curation pubmed
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
· Br J Cancer · 2010 · PMID 20628391 · validated civic_curation pubmed
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
· BMC Cancer · 2013 · PMID 23374602 · validated civic_curation pubmed
Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer.
· Oncotarget · 2015 · PMID 25788273 · validated civic_curation pubmed
P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer.
· BMC Cancer · 2014 · PMID 24708484 · validated civic_curation pubmed
EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.
· Chin J Cancer Res · 2014 · PMID 24653627 · validated civic_curation pubmed
TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.
· J Natl Cancer Inst · 2014 · PMID 24957073

Showing 226–250 of 370 publications

← Previous
1
…
9
10
11
…
15
Next →

· validated civic_curation

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.

· Clin Cancer Res · 2008 · PMID 18794099 · validated civic_curation pubmed

Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.

· BMC Cancer · 2009 · PMID 19775480 · validated civic_curation pubmed

Low thrombospondin 2 expression is predictive of low tumor regression after neoadjuvant chemoradiotherapy in rectal cancer.

· Am J Transl Res · 2015 · PMID 26807188 · validated civic_curation pubmed

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.

· Clin Cancer Res · 2014 · PMID 24947927 · validated civic_curation pubmed

HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.

· Am J Pathol · 2010 · PMID 20363910 · validated civic_curation pubmed

MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5.

· Carcinogenesis · 2015 · PMID 26442524 · validated civic_curation pubmed

Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.

· Ann Oncol · 2015 · PMID 26371285 · validated civic_curation pubmed

Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.

· Mol Cancer Ther · 2016 · PMID 27037411 · validated civic_curation pubmed

Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.

· Oncology · 2012 · PMID 22948721 · validated civic_curation pubmed

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

· Cancer Genet · 2013 · PMID 23313110 · validated civic_curation pubmed

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

· Eur J Cancer · 2015 · PMID 25673558 · validated civic_curation pubmed

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.

· Clin Cancer Res · 2015 · PMID 25589621 · validated civic_curation pubmed

Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.

· Oncology · 2016 · PMID 27404270 · validated civic_curation pubmed

SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer.

· Br J Cancer · 2002 · PMID 12237773 · validated civic_curation pubmed

HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.

· Clin Colorectal Cancer · 2017 · PMID 28223103 · validated civic_curation pubmed

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

· J Clin Oncol · 2008 · PMID 18316791 · validated civic_curation pubmed

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

· N Engl J Med · 2012 · PMID 23094721 · validated civic_curation pubmed

PIK3CA mutation is predictive of poor survival in patients with colorectal cancer.

· Int J Cancer · 2007 · PMID 17590872 · validated civic_curation pubmed